Tremella fuciformis-derived extracellular vesicles promote cutaneous regeneration through modulation of inflammatory microenvironment and regenerative responses.

Authors

Qian Yu, Zhenwei Gu, Sini Chen, Yueqiu Chen, Fenrou Chen, Haiyun Zhai, Lin Zhou

Published in

International immunopharmacology. Volume 191. Issue Pt 1. Pages 117558. Oct 22, 2026. Epub Oct 22, 2026.

Abstract

The clinical translation of extracellular vesicle (EV)-based therapies is currently hindered by the high manufacturing costs and limited scalability of conventional mammalian cell sources. Edible fungus-derived EVs have emerged as a promising alternative with potential advantages in scalability and cost-effectiveness. Here, we investigated the therapeutic potential of EVs derived from Tremella fuciformis fermentation broth (TFB-EVs) for cutaneous wound healing. In a murine full-thickness wound model, TFB-EV treatment significantly accelerated wound closure, reducing the residual wound area to 6.87 ± 2.95% by day 14, compared with 21.63 ± 4.82% in the control group (p < 0.001). Histological analysis confirmed improved tissue quality, characterized by enhanced re-epithelialization and more organized collagen deposition. Functionally, TFB-EV treatment was associated with a coordinated repair response characterized by attenuation of inflammatory and oxidative stress responses during the early repair stage and enhancement of regenerative responses during tissue remodeling. These antioxidant responses were consistent with Nrf2-associated cytoprotective signaling, while inflammatory modulation was associated with suppression of IL-17/TNF-associated pathways. Transcriptomic analysis revealed enrichment of PI3K-Akt-associated signaling pathways, together with regenerative phenotypes including relief of G0/G1 cell cycle arrest and enhanced proliferation, migration, and angiogenesis activity of relevant cellular models. Combined with the practical advantages of liquid fermentation, TFB-EVs represent a promising fungal-derived bioactive nanotherapeutic platform with potential for future translational development. This work provides a cross-kingdom therapeutic strategy for wound repair and highlights the potential of scalable biomanufacturing approaches for future EV-based therapies.

PMID:
42913193
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.